Suppr超能文献

自体造血干细胞移植可恢复系统性硬化症患者调节性 B 细胞的抑制能力。

Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients.

机构信息

Graduate Program on Biosciences and Biotechnology, School of Pharmaceutical Sciences of Ribeirão Preto.

Center for Cell-based Therapy, Regional Hemotherapy Center of the Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.

出版信息

Rheumatology (Oxford). 2021 Dec 1;60(12):5538-5548. doi: 10.1093/rheumatology/keab257.

Abstract

OBJECTIVES

The rationale of autologous haematopoietic stem cell transplantation (AHSCT) for autoimmune diseases is that high-dose immunosuppression eradicates autoreactive T and B cells and the infused autologous haematopoietic stem cells promote reconstitution of a naïve and self-tolerant immune system. The aim of this study was to evaluate the reconstitution of different B cell subsets, both quantitatively and functionally, in SSc patients treated with AHSCT.

METHODS

Peripheral blood was harvested from 22 SSc patients before transplantation and at 30, 60, 120, 180 and 360 days post-AHSCT. Immunophenotyping of B cell subsets, B cell cytokine production, signalling pathways and suppressive capacity of regulatory B cells (Bregs) were assessed by flow cytometry.

RESULTS

Naïve B cell frequencies increased from 60 to 360 days post-AHSCT compared with pre-transplantation. Conversely, memory B cell frequencies decreased during the same period. Plasma cell frequencies transiently decreased at 60 days post-AHSCT. IL-10-producing Bregs CD19+CD24hiCD38hi and CD19+CD24hiCD27+ frequencies increased at 180 days. Moreover, the phosphorylation of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase increased in B cells reconstituted post-AHSCT. Notably, CD19+CD24hiCD38hi Bregs recovered their ability to suppress production of Th1 cytokines by CD4+ T cells at 360 days post-AHSCT. Finally, IL-6 and TGF-β1-producing B cells decreased following AHSCT.

CONCLUSION

Taken together, these results suggest improvements in immunoregulatory and anti-fibrotic mechanisms after AHSCT for SSc, which may contribute to re-establishment of self-tolerance and clinical remission.

摘要

目的

自体造血干细胞移植(AHSCT)治疗自身免疫性疾病的原理是,大剂量免疫抑制可消除自身反应性 T 和 B 细胞,输注的自体造血干细胞促进幼稚和自身耐受的免疫系统重建。本研究旨在评估 AHSCT 治疗的 SSc 患者不同 B 细胞亚群的重建,包括数量和功能。

方法

采集 22 例 SSc 患者移植前和移植后 30、60、120、180 和 360 天的外周血。采用流式细胞术评估 B 细胞亚群的免疫表型、B 细胞细胞因子产生、信号通路和调节性 B 细胞(Bregs)的抑制能力。

结果

与移植前相比,幼稚 B 细胞频率从 60 天增加到 360 天。相反,记忆 B 细胞频率在此期间下降。浆细胞频率在移植后 60 天短暂下降。IL-10 产生的 Bregs CD19+CD24hiCD38hi 和 CD19+CD24hiCD27+频率在 180 天增加。此外,AHSCT 后 B 细胞中细胞外信号调节激酶 1/2 和 p38 丝裂原活化蛋白激酶的磷酸化增加。值得注意的是,CD19+CD24hiCD38hi Bregs 在 AHSCT 后恢复了抑制 CD4+T 细胞产生 Th1 细胞因子的能力。最后,AHSCT 后 IL-6 和 TGF-β1 产生的 B 细胞减少。

结论

综上所述,这些结果表明 AHSCT 治疗 SSc 后免疫调节和抗纤维化机制得到改善,这可能有助于重新建立自身耐受和临床缓解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验